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INTRODUCTION
Acute Myocardial Infarction is a serious and life threatening disorder. There are 
various risk factors for the development of Acute Myocardial Infarction. Of them, the 
most  important  and the one which is  causing havoc among South Asian and Indian 
population  is  the  relationship  between  abnormal  glucose  metabolism  and  Acute 
Myocardial Infarction. It is a well known fact that Diabetes Mellitus, a full blown form 
of  abnormal  glucose  metabolism is  associated  with  increased  risk  of  cardiovascular 
events  like  AMI,  unstable  angina,  Cerebrovascular  events  like  stroke  &  also  with 
peripheral vascular disease.
Whether  the  new  concept  of  Impaired  Glucose  Tolerance,  Impaired  Fasting 
Glucose also have similar effects on the morbidity and mortality of the patients with 
AMI & their relationship is either causal or casual needs to be urgently evaluated.
Also, the incidence of Impaired Glucose Tolerance, Impaired Fasting Glucose is 
increasing in the population especially among the Indians and South East Asians. The 
Impaired Glucose Tolerance,  Impaired Fasting Glucose are considered as prediabetic 
state,  in  the  contemporary  literature.  Whether  the  detection  of  an  individual  in  this 
prediabetic state & proper treatment with life style modification can bring down the risk 
of  future  cardio  vascular  events  like  Unstable  Angina,  AMI  are  questions  to  be 
answered.
With this background of Impaired Glucose Tolerance, Impaired Fasting Glucose 
metabolic abnormalities, their incidence in the patients with Acute Coronary Syndromes 
and  their  influence  on  the  outcome  of  the  cardio  vascular  events  with  respect  to 
mortality and morbidity is studied in this dissertation.
Also the effect of these prediabetic states on the left ventricular function in the 
post  myocardial  infarction period and on the functional  capacity of the individual is 
studied in detail in this thesis. 
AIMS OF THE STUDY
1. To  compare  and  contrast  the  in-hospital  outcomes  of  patients  with  Acute 
Myocardial infarction with normal Glucose Metabolism and Abnormal Glucose 
Metabolism – Impaired Glucose Tolerance.
2. To study the effect of Impaired Glucose Tolerance on the left ventricular function 
in these patients. 
3. To assess the functional capacity of the patients with Myocardial infarction with 
Impaired Glucose Tolerance.
REVIEW OF LITERATURE
Whether high but non diabetic blood glucose levels are predictive of increased 
mortality from Coronary Artery Disease is not a new issue. This topic was discussed in 
International collaborative group in 1979. The conclusion from this analysis was that 
there  was  no  consistent,  strong  and  graded  associated  between  asymptomatic 
hyperglycemic individuals and coronary artery disease.
Donaheu and Orchard reviewed the same question and concluded that glucose 
levels were related to Coronary artery disease risk, but whether the effect was linear or 
threshold was not clear in their study. 
Jarret et al concluded that the risk did not appear to be related linearly with the 
glucose levels, but is apparent only in the upper percentiles of glucose distribution.
In our study we report the association of Fasting Blood Sugar and 2 hour post 
glucose challenge blood sugar level with the in-hospital events like arrhythmias, heart 
failure, recurrent angina, pericarditis and death. 
We also report the association between fasting blood sugar and 2 hour glucose 
levels with Left ventricular function by analyzing the ventricular ejection fraction, end 
diastolic volume, end systolic volume, Wall motion score index and functional capacity 
as assessed by number of Mets in standard Bruce protocol Symptom limited Treadmill 
test before discharge from the hospital. 
Hyperglycemia in the absence of diagnosis of diabetes (blood sugar < 200mg %) 
is a common phenomenon in stress related conditions like Acute Myocardial Infarction. 
The  cause  of  this  hyperglycemia  is  primarily  from  excessive  release  of  counter 
regulatory hormones. 
Also,  hyperglycemia  refers  to  a  pre-diabetic  state  in  patients  who  are  not 
diagnosed to have diabetes and whose blood sugar levels are in the abnormal range. This 
state is referred to as Impaired Glucose Tolerance. 
Impaired Glucose Tolerance and Impaired Fasting Glucose are a continuum in the 
spectrum of disorder of glycemia.
Disorders of Glycemia : Etiologic Types and Stages
Stages
Types
Normoglycemia Hyperglycemia
Normal Glucose 
regulation
Impaired 
Glucose 
Tolerance or 
Impaired 
Fasting 
Glucose
Diabetes Mellitus
Non 
Insulin 
requiring
Insulin 
requiring 
for 
Control
Insulin 
requiring 
for 
survival
Type 1
Type 2
Other 
Specific 
Types
Gestational 
Diabetes
Source : American Diabetic Association
So, the disorder Impaired Glucose Tolerance and Impaired Fasting Glucose are 
considered as pre-diabetic state.
Multiple  studies  have  shown  that  hyperglycemia  in  the  diabetic  range  was 
associated with 3-4 fold increase in coronary artery disease risk and the outcome in the 
patients with diabetes was far more worse than that of the patients with out diabetes.
We in our study are establishing that whether this statement could be extrapolated 
to the patients who fall in Impaired Glucose Tolerance and Impaired Fasting Glucose 
range.
Recently, ACC/AHA guidelines have included the presence of Diabetes Mellitus 
as a major risk factor for coronary artery disease. Also, the Framingham Heart study 
reiterates that the patients with hyperglycemia in diabetic range have increased mortality 
and morbidity than the patients with normal glycemia.
A recent concept of Dysglycemia which includes Impaired Glucose Tolerance and 
Impaired Fasting Glucose is also under vogue. Sahay et al in his review has introduced 
the concept of Dysglycemia. The risk of coronary artery disease is high even at the time 
of  diagnosis  of  Type  2  Diabetes  Mellitus,  hence  the  pre-diabetic  states  are  also 
associated with increased risk of coronary artery disease.
Cardio vascular disease is leading cause of morbidity and mortality in patients 
with Diabetes Mellitus and the risk of Myocardial Infarction can be as high as in non 
diabetic individuals with history of Myocardial Infarction.
This has led to the National Cholesterol Educational Programme Adult Treatment 
Panel III (NCEP ATP III) to consider diabetes as Coronary Artery Disease equivalent.
It is now being recognised that revised blood glucose even below the threshold 
necessary to diagnose diabetes or even impaired glucose tolerance is associated with 
considerable increased risk of coronary artery disease. There appears to be a continuous 
relation  between  risk  of  coronary  artery  disease  and  raised  post  prandial  glucose 
concentration that extends from barely elevated levels right into the diabetic range.
That the glucose concentration associated with increased risk of Coronary Artery 
Disease are lower than those required for diagnosis of diabetes should not be surprising. 
Since  these  criteria  are  based  on  specific  glucose  concentration  above  which  the 
individuals are at risk for development of nephropathy and retinopathy and not cardio 
vascular disease.
Although post prandial glucose levels above which the patients are at an increased 
risk of coronary artery disease is not yet defined, it may be as low as 98 mg %. Since 
this  value  is  much lower  than that  which would  qualify  for  diagnostic  of  Impaired 
Glucose Tolerance. The term Dysglycemia is suggested to define the range of glucose 
concentration associated with risk of Coronary Artery Disease (Gerstein et al). 
Dysglycemia therefore includes in addition to the pre-diabetic states (Impaired 
Glucose Tolerance and Impaired Fasting Glucose), blood glucose values much below 
this threshold.
Impaired Glucose Tolerance & Impaired Fasting Glucose places the individuals at 
risk  of  developing  diabetes  mellitus  and  its  complications.  Both  Impaired  Glucose 
Tolerance and Impaired Fasting Glucose appear well before type 2 diabetes mellitus is 
diagnosed and they present an opportunity for intervention to reduce the future burden 
of  diabetes  and  associated  coronary  artery  disease  risk  to  the  individual  and to  the 
community. 
Diagnostic values for Oral Glucose Tolerance Test (OGTT) for Diabetes Mellitus & 
other categories of Hyperglycemia
Whole Blood Glucose Plasma Glucose
Venous Capillary Venous Capillary
Diabetes 
Mellitus 
Fasting
2  hr  after  75 
gm  glucose 
load
> 6.1 (> 110)
>10.0 (> 180)
> 6.1 (> 110)
>11.1 (> 200)
> 7.0 (> 126)
>11.1 (> 200)
> 7.0 (> 126)
>12.2 (> 220)
Impaired 
Glucose 
Tolerance 
Fasting Value
2  hr  after  75 
gm  glucose 
load
< 6.1 (< 110)
6.7 – 10.0
(120-180)
< 6.1 (<110)
7.8 – 11.1
(140-200)
< 7.0 (<126)
7.8 – 11.1
(140-200)
< 7.0(<126)
8.9-12.2
(160-220)
Impaired 
Fasting 
Glucose
Fasting Value
2  hr  after  75 
gm  glucose 
load
5.6 – 6.1
(100-110)
<6.7 (<120)
5.6-6.1
(100-110)
<7.8 (<140)
6.1-7.0
(110-126)
<7.8 (<140)
6.1-7.0
(110-126)
<8.9 (<160)
Source : American Diabetic Association
Note :
1. Values are given in mmol/lt, values given in the parenthesis are mg/dl.
2. The plasma glucose is 15% higher than the whole blood glucose. In a fasting state 
the ‘Venous and Capillary Whole blood glucose is one and the same. But varies in 
the postprandial  state.  But  with plasma glucose both the venous and capillary 
values are and the same. 
3. WHO recommends 75 gm glucose load for adults and pregnant women.
4. Fasting value alone  is  considered less  reliable,  because  true fasting cannot  be 
assured and spurious diagnosis of diabetes may readily occur.
5. 1 mmol/l x 18 = mg % (conversion formula).
Importance of Impaired Fasting Glucose and Impaired Glucose Tolerance:
There is no clear consensus with current evidence on whether Impaired Fasting 
Glucose  and Impaired  Glucose  Tolerance  should  be  classified  as  diseases.  But  they 
clearly represent risk factors and risk markers for diabetes and cardio vascular disease 
respectively.  Both  Impaired  Fasting  Glucose  and  Impaired  Glucose  Tolerance  are 
similarly associated with increased risk of diabetes. But Impaired Glucose Tolerance is 
strongly associated with cardio vascular disease outcomes.
Risk of hyperglycemia
Several  explanations  may  account  for  the  observed  increased  risk  between 
hyperglycemia  and  poor  prognosis  after  myocardial  ischemia.  Metha  et  al  in  his 
observation  has  found  that  hyperglycemia  may  be  directly  toxic  to  ischemic 
myocardium. Increase in the lactate content and intra cellular acidosis in the cells of 
ischemic myocardium are seen in patients with hyperglycemia. 
Hyperglycemic patients are relatively deficient in insulin and this leads to both 
reduced peripheral uptake of glucose and may lead to decrease in the availability of 
glycolytic  substrate  for  cardiac  muscle  utilization  and  increase  in  free  fatty  acid 
concentration  in  ischemic  musculature.  These  changes  may  reduce  myocardial 
contractility even at increased oxygen concentration. It  also increases the myocardial 
oxygen demand for the amount of myocardial work done leading to pump failure, and 
promote arrhythmias. (Sarah E.Capes et al)
According to Sarah E.Capes et al in meta analysis of 15 articles hyperglycemia 
is  not  simply  an  epiphenomenon  of  stress  response  mediated  by  cortisol  and  nor-
adrenaline.  It  is  associated  increased  risk  of  in-hospital  mortality,  increased  risk  of 
congestive heart failure and cardiogenic shock. 
Hyperglycemia is a reflection of relative insulin deficiency and is associated with 
increased lipolysis, and excess circulating Free Fatty Acids (FFA), this effect  may be 
exaggerated in cases of acute stress like Acute Myocardial Infarction.
Free Fatty Acids (FFA), although  normally the substrate of choice for healthy 
myocardium, are toxic to ischemic myocardial and may lead to damaged cardiac cell  
membrane, calcium overload, and arrhythmias. 
Moreover in animal studies conducted by Mjos et al, high concentration of Free 
Fatty Acids during myocardial ischemia causes increase in myocardial oxygen demands 
and decreased myocardial contractility. 
Beta blockers suppress this release of Free Fatty Acids in patients with myocardial 
infarction  and  lessens  the  harmful  effects  of  hyperglycemia  and  insulin  deficiency. 
(Malmberg et al)
Insulin deficiency may also limit the ability of cardiac muscle to take up glucose 
for anaerobic metabolism. In animal studies by         Ebreli  et al,  preservation of 
myocardial function during ischemia correlates with increased uptake and metabolism of 
glucose.
The potential importance of insulin deficiency is also highlighted by randomised 
controlled trials in which insulin administered to patients without diabetes who have had 
acute myocardial infarction have improved clinical outcomes. 
A similar observation was reported in DIGAMI study in which 620 patients with 
diabetes  who  had  acute  myocardial  infarction  were  randomly  assigned  an  insulin 
infusion followed by multidose subcutaneous insulin treatment for at least 3 months or 
conventional management. In that study, insulin lowered mortality by 28% (p 0.11) after 
mean follow up of 3-4 yrs and high glucose concentration on admission predicted higher 
risk of mortality.
Acute  hyperglycemia  may  also  precipitate  an  osmotic  diuresis.  The  resulting 
volume  depletion  may  interfere  with  the  Frank  Starling  mechanism,  an  important 
compensatory mechanism for the failing Left Ventricle in which increased end diastolic 
volume leads to increased stroke volume. 
Hyperglycemia  may  be  a  marker  of  more  extensive  cardiac  damage  in  acute 
myocardial infarction, more extensive cardiac damage may lead to a greater rise in stress 
hormones promoting glycogenolysis and may also increased the risk of congestive heart 
failure and mortality.
Hyperglycemia  in  Impaired  Glucose  Tolerance  is  associated  with  hypertension, 
dyslipidemia and insulin resistance, a complex situation called Metabolic Syndrome - X. 
According to National Cholesterol Educational Programme Adult Treatment Panel 
III, metabolic syndrome is diagnosed by following criteria.
Risk factors Defining Levels
Abdominal  obesity  (Waist 
Circumference)
     Men
    Women
> 102cm (> 40 in)
> 88 cm (> 35 in)
Triglycerides > 150 mg%
HDL – C
    Men
    Women
< 40 mg%
< 50mg%
Blood Pressure > 130 / 80 mm Hg
Fasting Glucose > 110 mg %
Diagnosis is established when > 3 of these risk factors are present.
Criteria for Hypertriglyceridemic waist in men 
Character Criteria
Triglyceride
Waist
> 2.0 mmol/l
> 90cm
Pathophysiology of Hyperglycemia in causing vascular disease
Abnormalities in endothelial and vascular smooth muscle cell function as well as 
propensity to thrombosis, contribute to atherosclerosis and its complications. Endothelial 
cells  are  biologically  active  and  produce  substances  that  maintain  intra  vascular 
hemostasis. It also ensures adequate blood flow and nutrient delivery while preventing 
thrombosis and leukocyte diapedesis.
Most important of the substances produced by endothelium is Nitric Oxide (NO). 
Metabolic derangements like hyperglycemia and hyperlipidemia increase free fatty acid 
liberation and insulin resistances and prevent Nitric Oxide production. 
Impaired Glucose Tolerance mediate the abnormalities in endothelial cell function 
by affecting synthesis or increased degradation of Nitric Oxide.
Experimental  evidence  supports  that  hyperglycemia  decreases  endothelium 
derived Nitric Oxide. Hyperglycemia induces a series of cellular events that increases 
the production of Reactive Oxygen Species like super oxide anion that inactive Nitric 
Oxide to form peroxynitrite. 
Hyperglycemia  may  initiate  this  process  by  increasing  super  oxide  anion 
production  via  mitochondrial  electron  transport  chain.  Super  oxide  then  promotes  a 
cascade of endothelial process that produce oxygen derived free radicals which activate 
second messengers like Protein Kinase C (PKC).
Mitochondrial production of super oxide anion also increases the production of 
Advanced Glycation End products (AGE). These glycated proteins adversely affect the 
cellular function by altering the protein function and by activating the Receptors for 
Advanced Glycation End products (RAGE). Advanced Glycation End products perse 
increase  the  production  of  oxygen  derived  free  radicals.  Receptors  for  Advanced 
Glycation  End  products  activation  increases  intra  cellular  enzymatic  super  oxide 
production.
Hyperglycemia induced oxidative stress increases the levels of Asymmetric Dimethyl 
Arginine  (ADMA),  a  competitive  antagonist  of  Nitric  Oxide  Synthase  (NOS),  by 
impairing  the  activity  of  dimethyl  arginine   dimethyl  aminohydrolase  to  metabolise 
Asymmetric Dimethyl Arginine (ADMA).
Hyperglycemia also increases the production of lipid second messenger Diacyl 
Glycerol  (DAC).  Diacyl  Glycerol  causes  membrane  translocation  and  activation  of 
Protein Kinase C (PKC), which decreases endothelium dependent vaso relaxation. 
Free Fatty Acids liberation and Endothelial function 
Circulating  Free  Fatty  Acids  are  increased  in  Impaired  Glucose  Tolerance, 
because of their excess liberation from adipose tissue and diminished uptake by skeletal 
muscle. Free Fatty Acids impair endothelial function by increasing the production of 
oxygen derived free radicals, activation of Protein Kinase C (PKC) and exacerbation of 
dyslipidemia. Both hypertriglyceridemia and low High Density Lipoprotein (HDL) have 
been associated with endothelial dysfunction. 
Impaired Glucose Tolerance, Thrombosis and Coagulation 
Platelet function is also abnormal in Impaired Glucose Tolerance. Expression of 
both glycoprotein Ib and IIb / IIIa are increased, augmenting the platelet von Willebrand 
Factor  (vWF)  and platelet  fibrin  interaction.  Hyperglycemia  further  changes  platelet 
function  by  impairing  calcium  hemostasis.  It  also  alters  many  aspects  of  platelet 
activation and aggregation, including platelet confirmation and release of mediators. 
Plasma  coagulation  factors  (eg.  Factor  VII  and  Thrombin)  and  lesion  based 
coagulants  (tissue  factors)  are  increased  in  impaired  glucose  tolerance.  Endogenous 
anticoagulation like thrombomodulin and protein C are decreased. Also the production 
of Plasminogen Activator Inhibitor (PAI-1), a Fibrinolytic inhibitor is increased. Thus, a 
propensity  for  platelet  activation  and  aggregation  coupled  with  a  tendency  for 
coagulation is relevant for an increased risk of thrombosis complicating plaque rupture 
and atherosclerotic coronary artery disease. 
Hyperglycemia also causes increase in local and systemic inflammation during 
acute myocardial infarction. Studies suggest that acute “T” cell activation may play a 
role in plaque instability  and acute clinical manifestation of coronary atherosclerosis 
(Ross et al).
According to Raffaele Marfella et al hyperglycemia during myocardial infarction 
is associated with increased levels of inflammatory markers,  enhanced expression of 
cytotoxic  ‘T’ cells  and  reduced  expression  of  ‘T’ cells  implicated  in  limitation  of 
immune process.
Insulin is found to be a central factor in inhibiting cytokine release like IL – 8, 
decreased C-Reactive Protein (CRP) levels and inhibiting T cell activation. So, patients 
with insulin resistance like impaired glucose tolerance have increased cytokine release, 
increase in the levels  of           C-Reactive Protein (CRP) in  blood and increased 
activation of T cells. 
Also hyperglycemia is associated with increased Troponin levels probably as a 
consequence of more extensive myocardial damage. 
Raffaele  Marfella  et  al  in  a  study  further  found  out  that,  hyperglycemia 
positively correlated with both infarct segment length and Wall Motion Score Index. 
With  increasing  blood  sugar  levels  wall  motion  score  index  increased  and  with 
increasing wall motion score index patient had poor prognosis. Wall motion score index 
positively correlated with extent of myocardial infarction. A wall motion score index of 
greater than 1.7 correlated approximately with 20% myocardial infarction by perfusion 
scan studies. 
The  increase  in  Myocardial  Performance  Index  (MPI)  which  measures  both 
systolic  and  dialostic  parameters  of  ventricular  function  indicates  worst  functional 
outcome after myocardial infarction in hyperglycemic patients. The diminished diastolic 
filling  time,  prolongation  of  mitral  regurgitation  and  decreased  ejection  time  in 
hyperglycemic patients suggest, hyperglycemia may influence cardiac synchronisation 
after acute myocardial infarction. 
Dyssynchrony  between  right  ventricular  and  left  ventricular  contraction  are 
independent predictors of heart failure and cardiac mortality in patients with congestive 
cardiac failure. 
MATERIALS AND METHODS
The study was carried out with the aim of comparing the in-hospital events like 
Arrhythmias,  congestive  heart  failure,  recurrent  angina,  Pericarditis  & death  among 
patients with acute ST elevation myocardial infarction eligible for thrombolysis with 
normal glucose metabolism and  Impaired Glucose Tolerance. 
Patients  admitted  in  our  Intensive  coronary  care  unit  with  acute  ST elevation 
Myocardial infarction were divided into two groups based on their glucose metabolism 
as patients with normal glucose metabolism and those with Impaired Glucose Tolerance. 
Acute ST elevation myocardial  infarction was defined as typical  chest  pain of 
ischemic origin lasting for > 20 minutes with ECG evidence of ST elevation of atleast 
1mm in 2 contiguous limb leads and atleast  2mm in 2 contiguous chest  leads,  with 
typical rise and fall of biochemical markers of myocardial necrosis.
If the patients have any of the 2 above criteria, he/she was included as a patient 
with acute ST elevation Myocardial Infarction. Eligibility criteria for thrombolysis was 
scrutinized as per ACC/AHA guidelines for management of ST elevation myocardial 
infarction. All patients with pre-existing Diabetes Mellitus or blood sugar level in the 
diabetic range were excluded from the study. 
All the study and control patients were treated with thrombolysis with Injection 
Streptokinase 1.5 million units in 100ml of normal saline to be run over 1 hour. Other 
medications were given as  per  the  need of  the patients  and at  the discretion of  the 
treating physician.
At admission all patients were drawn blood for random blood glucose estimation. 
On the next morning after overnight fasting of 10-16 hours an Oral Glucose Tolerance 
Test was performed as per American Diabetic Association Recommendation.
A fasting blood sample was taken before giving glucose load. The subject was 
made to drink 75gms of glucose dissolved in 250-300ml of water. The glucose load was 
consumed over a period of 5 minutes. Blood samples are collected in fluoride – oxalate 
test tubes to prevent Red Blood corpuscles from metabolizing glucose.
Venous plasma collected from the patients were estimated for glucose by glucose 
oxidase method in our biochemistry laboratory. The values were expressed in mg %.
Lipid Profile
Blood for lipid estimation was collected after an overnight fast within 24-48 hours 
of admission. Cholesterol and Triglycerides were measured by enzymatic calorimetric 
assays. High Density Lipoprotein and Low Density Lipoprotein cholesterol measures 
were done enzymatically using selective solubilisation method.
Glycosylated Hemoglobin
Glycosylated Hemoglobin  was estimated by cation-exchange resin method using 
Monozyme’s Glycohemin kit. It is a rapid 10 minutes assay with conversion chart from 
Glycosylated Hemoglobin A1% to Glycosylated Hemoglobin A1c%. The normal value 
for Glycosylated Hemoglobin A1 were between 6.0 to 8.7% which corresponded to  4.48 
to 6.44 for Glycosylated Hemoglobin A1C.
A good clinical history with documentation of duration of chest pain and previous 
history  of  Myocardial  Infarction,  Angina,  Hypertension  was  taken.  Detailed  clinical 
examination at admission was done as per our intensive coronary care protocol. Systolic 
and diastolic Blood Pressure were measured using mercury sphygmomanometer. Phase I 
of korotkoff’s sound was taken as Systolic Blood Pressure and phase V as Diastolic 
Blood Pressure. Killip’s class was ascertained for every single subject at admission.
After  thrombolysis  and  during  hospital  stay  other  parameters  like  successful 
thrombolysis, defined as greater than 50% resolution of the ST segment elevation at 90 
minutes after Injection Streptokinase, complications like Arrhythmias, Congestive heart 
failure, Recurrent angina, development of pericarditis and death were monitored. 
Complications were treated as per standard treatment protocol like cardioversion 
for  hemodynamically  unstable  ventricular  tachycardia  and  ventricular  fibrillation. 
Complete heart block was treated with transvenous temporary pacing. Congestive heart 
failure was treated with diuretics,  inotropes,  and vasodilators.  Recurrent  Angina was 
treated with nitroglycerin infusion, intravenous heparin and beta blockers. 
An day 3 of admission all patients underwent two dimensional echo cardiography 
and Doppler  evaluation.  Left  Ventricular  function  was  assessed  using  End  Diastolic 
Volume, End Systolic Volume and Ejection Fraction. Ejection Fraction was calculated 
by Modified Simpson’s method. 
All the 16 segments as per American society of echocardiography classification 
were carefully investigated for wall motion abnormalities with naked eye and M – mode 
examination.  Wall  motion  score  was  ascertained  as  1  if  the  segment  was  normally 
contracting. A score of 2 was given for hypo kinetic segment, 3 for akinetic segment. 
Dyskinetic segment was given a score of 4, and aneurysm was scored at 5.
Wall motion score index was calculated using the  formula ,
Wall motion score index = Sum of wall motion scores  ÷  number of segments 
visualized. 
Presence or absence of Left Ventricular clot was assessed using two dimensional 
echo cardiography.
All  the  subjects  with  out  Left  Ventricular  clot  underwent  symptom  limited 
Treadmill Test by Bruce protocol and their functional capacity was assessed an day 5-7 
before discharge from the hospital. The functional capacity was calculated as number of 
Mets of exercise the patients was able to perform before achieving either the target heart 
rate or development of symptoms necessitating stopping of the procedure.           
Body mass index was calculated for all patients using the formula
    Weight in kg
Body Mass Index = 
(Height)2 in metre
To ensure correct reading, for height, the patients were made to stand on a flat  
surface against a wall bare footed and measurement were taken in cms. Weight was 
measured in kilograms by using the same weighing scale for all the patients. 
Measurement of  waist circumference 
Waist circumference was measured at mid point between the ribcage and 2 cm 
above the top of the iliac crest. Two measurement of waist circumference were made and 
the average was taken.
Waist circumference of > 103 cm in male and > 88 cm in female were considered 
abnormal.
All  the  parameters  and  variables  were  tabulated  in  a  master  chart  and  were 
analysed  by  computer  analysis.  Data  were  analysed  utilizing  the  software  – 
Epidemiological information package – 2002 (EPI Info 2002) developed by the center 
for disease control and prevention, Atlanta for World Health Organisation.
Mean, Standard deviation and ‘p’ values were calculated using this package. Chi-
square test was used to find out the significance of relationship between the groups and 
other variables.  
RESULTS AND OBSERVATIONS
The relationship of parameters in study group i.e., patients with Impaired Glucose 
Tolerance and control group i.e., normal glucose metabolism revealed the following,
Sex  distribution  between  the  study  group  n=75  and  control  group  n=25 were 
similar.
53 patients (70.7%) in the study group and 19 patients (76%) in the control group 
were males. The ‘p’ value was not significant showing there was no selection bias. 
Table - 1
Sex Distribution
Sex Study group 
(n=75)
Control Group 
(n=25)
‘p’
No. % No. %
Males
Females
53
22
70.7
29.3
19
6
76
24
0.797
70.7
29.3
76
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Similarly  the  distribution  of  myocardial  infarction  also  did  not  slow  any 
significant ‘p’ value. 42 patients (56%) in study group and 15 patients (60%) in control 
group had Anterior Wall Myocardial Infarction.
Table - 2
Distribution of Myocardial Infarction Location
Myocardial 
Infarction 
Location
Study group 
(n=75)
Control Group 
(n=25)
‘p’
No. % No. %
Anterior Wall
Inferior Wall
42
33
56
44
15
10
60
40
0.9071
56
44
60
40
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On analyzing the Killip Class, 5 patients (6.7%) were in Killip Class I, 19 patients 
(25.3%) in Class II, 28 patients (37.3%) in class III and 23 patients (30.7%) in class IV, 
in the study group and 11 patients (44%) in class I, 12 patients (48%) in class II and 2 
patients (8%) in class III in the control group.
Table - 3
Killip’s Class Distribution
Killip’s Class Study group 
(n=75)
Control Group 
(n=25)
‘p’
No. % No. %
I
II
III
IV
5
19
28
23
6.7
25.3
37.3
30.7
11
12
2
-
44
48
8
-
0.0001(Sig.)
6.7
44
25.3
48
37.3
8
30.7
0
0
5
10
15
20
25
30
35
40
45
50
I II III IV
Study Group Control Group
The mean Killip class was 2.92  ±  0.91 in the study group and 1.64  ±  0.63 in 
control group with significant ‘p’ value of 0.0001.
Previous history of hypertension also correlated well with in the study group with 
41.3% of patients (31) were taking treatment for hypertension. 
On analyzing the complications, Arrhythmias were more common in the study 
group.  A total  of  28  patients  (37.3%)  had  some  form  of  Arrhythmias  Ventricular 
Tachycardia / Ventricular Fibrillation or Complete Heart Block in the study group. Only 
3 patients (12%) had Arrhythmias in the control group. The incidence of Arrhythmias 
was more in the study group with significant ‘p’ value of 0.0338.
Ventricular Tachycardia was seen in 10 patients (13.33%), Complete Heart Block 
in 12 patients (16%), Bifascicular Block in 4 patients (5.33%) and Others in 2 patients 
(2.67%).
Table - 4
Spectrum of Arrhythmias
 Arrhythmias Study group 
(n=75)
Control Group 
(n=25)
No. % No. %
VT / VF
CHB
Bifascicular block
Others
10
12
4
2
13.33
16
5.33
2.67
2
1
0
0
8
4
0
0
13
8
16
4 5
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Study Group Control Group
Congestive heart failure was present in 57 patients (76%) in the study group and 4 
patients (16%) in the control group. Congestive heart failure was associated with poor 
outcome in our study. This also had a significant ‘p’ value of 0.0001.
Table - 5
Comparison of Congestive Heart Failure between the two groups
Congestive 
Heart Failure
Study group 
(n=75)
Control Group 
(n=25)
‘p’
No. % No. %
Present
Absent
57
18
76
24
4
21
16
84
0.0001 
76
24
16
84
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The  relative  incidence  of  recurrent  angina  needing  nitroglycerine  and  heparin 
therapy were seen in 28 patients (37.3%) in the study group and only 3 patients (12%) in 
the control group. (p=0.0338).
Similarly there were 32 patients (42.7%) with Left Ventricular clot in the study 
group and only 1 patient (4%) in the control group. (p=0.0009).
Table - 6
Incidence of Left Ventricular Clot
Left Ventricular 
Clot
Study group 
(n=75)
Control Group 
(n=25)
‘p’
No. % No. %
Present
Absent
32
43
42.7
57.3
1
24
4
96
0.0009 
42.7 57.3
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Death was seen a 11 patients in the study group (14.3%) and one patients (4%) in 
the control group. The percentage of patients was 3.5 times higher in the study group 
than in the control group. There was a statistically significant difference. (p=0.0414).
Table - 7
Percentage of Death
Death Study group 
(n=75)
Control Group 
(n=25)
‘p’
No. % No. %
Yes
No
11
64
14.7
85.3
1
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4
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0.1414
14.7
85.3
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Table - 8
Mean Values of the Parameters in the Study and Control Groups
Parameters Study Control ‘p’
Mean S.D. Mean S.D.
Age 54.9 9.9 52.2 11.5 0.3671
Chest pain duration 6.4 2.3 6.5 1.9 0.9692
SBP 112.4 33.1 101.7 6.4 0.4722
DBP 74.5 15.9 73.2 5.7 0.9246
PR 83.4 23.5 83.4 13.3 0.7829
Hb A1C 5.5 0.27 5.4 0.26 0.1954
RBS 176.7 16.6 123.5 11.7 0.0001 
FBS 110.7 9.7 84.7 12.3 0.0001 
BS 1 hour 182.2 12.6 119 15.3 0.0001 
BS 2 hour 163.9 11 102 11.9 0.0001 
TC 193 46 168.7 33.2 0.0131
TGL 157.4 51.9 132.8 33.2 0.0406
HDL 39.9 3.8 39.9 3.5 0.8678
LDL 112.9 39.3 99.4 31.6 0.075
VLDL 33 12.5 27.3 6.7 0.038
BMI 28.2 1.6 20.7 0.9 0.0001
Waist 103.9 5.4 89.5 4.1 0.0001
EF 40.8 4.6 49.6 3.7 0.0001
EDV 117.2 15.2 102 9.9 0.0001
ESV 69.2 14.1 51.8 7.7 0.0001
WMSI 1.98 0.27 1.45 0.18 0.0001
METS 5.02 0.5 6.47 0.96 0.0001
When  the biochemical markers of Impaired Glucose Tolerance were analysed all 
the  variables,  Random  blood  sugar,  Fasting  blood  sugar  and  2  hour  post  glucose 
challenge blood sugar were showing high statistical significance between the study and 
the control group.
When  analyzing  the  lipid  profile  of  both  the  groups  Total  Cholesterol, 
Triglycerides,  Very  Low  Density  Lipoproteins  showed  positive  correlation  in  the 
Impaired Glucose Tolerance group.
The  Body  Mass  Index  and  the  Waist  Circumference  were  also  found  to  be 
abnormal in the study group when compared to the control group. 
The  age  of  the  study  group  and  the  control  group  were  similar  without  any 
statistical difference. Also the duration of chest pain i.e., the door to needle time did not 
show any statistically significant difference between the two groups. These points were 
reiterated here to show that there was no selection bias among the two groups. 
The systolic blood pressures, the diastolic blood pressure and the pulse rate at 
admission also did not show any significant difference between the two population of 
patients. 
The mean Hemoglobin A1C was 5.5 ±  0.27 in the study group and 5.4 ±  0.26 in 
the control group suggesting that all these patients have not been known diabetics over 
the previous 120 days. 
Random Blood Sugar showed a significant p value when compared with control 
patients. Study patients had a random blood sugar of 176.7  ±  16.6 mg% and control 
patients had 123.5 ±  11.7 mg % (p=0.0001).
Fasting Blood Sugar also showed a significant ‘p’ value with study patient having 
a mean of 110.7 ±  9.7 mg % and controls 84.7 ±  12.3 mg% (p=0.0001).
The mean 2 hour blood sugar was 163.9 ±  11.0 mg% in the study group and 102 
±  11.9 mg% in the control group with a significant ‘p’ of 0.0001.
Table - 9
Comparison of Blood Sugar Levels
Blood Sugar 
Level
Study Control ‘p’
Mean S.D. Mean S.D.
Random 176.7 16.6 123.5 11.7 0.0001 
Fasting 110.7 9.7 84.7 12.3 0.0001 
2 hour 163.9 11 102 11.9 0.0001 
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Similarly Total Cholesterol and Triglycerides were significantly different among 
patients between study group and control group. Total Cholesterol was 193 ±  46 mg% 
in the study group and Triglycerides was 157.4  ±  51.9 mg% in the study group as 
against 168.7 ±  33.2 mg% and 132.8 ±  33.2 mg% in the control group (p<0.05).
Even though the mean Low Density Lipoproteins was 112.9 ±  39.3 mg% in the 
study group as against  99.4  ±  31.6 mg% in the control group, the p value was not 
significant (p=0.075).
Table - 10
Comparison of Lipid Profile
Lipids Study Control ‘p’
Mean S.D. Mean S.D.
TC 193 46 168.7 33.2 0.0131
TGL 157.4 51.9 132.8 33.2 0.0406
HDL 39.9 3.8 39.9 3.5 0.8678
LDL 112.9 39.3 99.4 31.6 0.075
VLDL 33 12.5 27.3 6.7 0.038
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The Body Mass Index in the study group was 28.2 ±  1.6 as against 20.7 ±  0.9 in 
the control group which was statistically significant (p=0.0001).
Similarly Waist circumference was 103.9 ±  5.4 cm in the study group and 89.5 ±  
4.1 in the control group (p=0.0001). 
When the indices of left ventricular function were analysed, ejection fraction, end 
diastolic volume, end systolic volume were significantly different between the study and 
the control groups. The mean ejection fraction was 40.8  ±  4.6 in the study group and 
49.6 ±  3.7 in the control group which was statistically significant (p=0.0001).
Table - 11
Comparison of Ejection Fraction
LV function Study Control ‘p’
Mean S.D. Mean S.D.
Ejection Fraction 40.8 4.6 49.6 3.7 0.0001
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When end diastolic volume and end systolic volume were compared the mean 
were 117.2 ±  15.2 ml and 69.2 ±  14.1 ml in the study group and 102 ±  9.9 ml and 51.8 
±  7.7  ml  in  the  control  group respectively  which were  statistically  very  significant 
(p=0.0001).
Table - 12
Comparison of Ventricular Volumes
Ventricular 
Volume
Study Control ‘p’
Mean S.D. Mean S.D.
End Diastolic 117.2 15.2 102 9.9 0.0001
End Systolic 69.2 14.1 51.8 7.7 0.0001
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When Wall Motion Score index was compared between the two groups, the mean 
score  was  1.98  ±  0.27  in  the  study  group  which  showed  larger  segmental  loss  of 
contractility  as  against  1.45  ±  0.18  in  the  control  group.  The  p  value  was  again 
significant (p=0.0001).
Table - 13
Comparison of Wall Motion Score Index
Regional Wall 
Motion
Study Control ‘p’
Mean S.D. Mean S.D.
WMSI 1.98 0.27 1.45 0.18 0.0001(Sig.)
1.45
1.98
Control Group Study Group
Similarly  functional  capacity  as  assessed  by  pre-discharge  Symptom  limited 
Treadmill test using Bruce protocol the mean Mets achieved before stopping the test was 
5.02 ±  0.5 in the study group and 6.47 ±  0.96 in the control group (p=0.0001).
Wall Motion Score Index
Table - 14
Comparison of Functional Capacity
Functional 
Capacity
Study Control ‘p’
Mean S.D. Mean S.D.
Mets 5.02 0.5 6.47 0.96 0.0001
5
6.5
Control Group Study Group
Fasting Blood Sugar < 110 mg% was taken as cut of points and analysis was done 
to find out the distribution in the study and the control group, 41 patients (54.7%) had 
abnormal  Fasting  Blood  Sugar  in  the  study  group  and  non  in  the  control  group 
(p=0.0001).
Similarly  2  hour  blood  sugar  of  >  140  mg  % showed  statistically  significant 
association in the study group. 
27  patients  (36%)  had  abnormal  total  cholesterol  values  as  against  3  patients 
Metabolic equivalents
(12%)  in  the  control  group.  35  patients  (46.7%)  had  abnormal  Triglycerides  levels 
against 5 (20%) patients in the control group. 
Similarly, 43 patients (52.3%) had Low Density Lipoproteins levels of >100mg% 
in the study group and only 7 patients (28%) had such values in the control group.  
Abnormal Waist circumference (>103 cm in males and > 88cm in females) were 
present in 49 (65.3%) of the study patients as against none in the control group.
Thus the percentage of patients with abnormal values of Fasting Blood Sugar, 2 
hour Blood Sugar, Total Cholesterol,  Triglycerides, Low Density Lipoproteins, Waist 
Circumference  and Body  Mass  Index  were  significantly  different  from those  of  the 
control cases. 
DISCUSSION
Impaired Glucose Tolerance as per the creiteria is associated with increased in-
hospital  events  like arrhythmia,  Congestive Heart  Failure and mortality according to 
large number of studies quoted in the bibliography. 
The basis of our study was a meta analysis from the Lancet 2000; 355: 773-78 by 
Sarah E. Capes et al.
Sarah E. Capes et al analysed about 15 studies in which patients without diabetes 
but  increased  glucose  concentration  above  the  normal  level  with  Acute  Myocardial 
Infarction  were  observed  for  in-hospital  events.  The  study  conclusion  was  that 
hyperglycemia  with  myocardial  infarction  was  associated  with  increased  risk  of  in-
hospital mortality in patients without diabetes. The risk of Congestive Heart Failure and 
cardiogenic  shock  were  also  increased  in  those  patients  without  diabetes  but  with 
hyperglycemia of non diabetic range. 
Similar results were obtained in our study, where we analysed about 75 patients 
with Impaired Glucose Tolerance and compared them with patients with normal glucose 
tolerance with both these groups had Acute ST elevation Myocardial Infarction.
There was a significant difference in various killip classes between the 2 groups 
with a mean of 2.92 ±  0.9 in Impaired Glucose Tolerance Group and 1.64 ±  0.63 in the 
control group. (p < 0.0001).
The  incidence  of  in-hospital  events  like  arrhythmias,  Ventricular  Tachycardia, 
Ventricular Fibrillation, Non-sustained ventricular Tachycardia, Complete Heart Block, 
Bifascicular block were increased in the study group as compared to the control group.
Significant difference is the incidence of Congestive Heart Failure was also seen 
in  the study group with about  76% of patients  had clinically  significant  Congestive 
Heart Failure requiring treatment, unlike only 16% of patients in the control group with 
a statistically significant p of 0.0001.
Similarly,  the incidence of  recurrent  angina was also significantly more in the 
study group than in the control group. 
The relative incidence of death was 14.7% is the study group and only 4% in the 
control groups and most of the deaths were either due to Congestive Heart Failure or 
Arrhythmias or Recurrent angina or a combination of these complications. 
All  the  patients  who  died  had  Congestive  Heart  Failure  with  Arrhythmias 
contributing in about 45% patients along with Congestive Heart Failure and Recurrent 
Angina  contributing  45%  among  all  the  death.  About  2  patients  (18%)  had  only 
Congestive Heart Failure as major cause of their death. 
When other traditional risk factor like smoking was considered, about 42 patients 
(56%) were smokers in the study group and 18 patients (72%) were in the control group. 
Still, death was about 3-4 times higher in the Impaired Glucose Tolerance as compared 
to that of the normoglycemic group.
Hyperglycemia was the basic culprit  causing the increased incidence of all  in-
hospital event rates in the Impaired Glucose Tolerance group. 
Hyperglycemia also contributed for the decreased Left Ventricular function in the 
study group when compared to that of the control group. The ejection fraction which is 
the traditional index of Left Ventricular function was statistically significantly different 
in both the groups. 
In the study group ejection fraction was around 40.8  ±  4.6 and in the control 
group 49.6 ±  3.2, which was statistically significant.
Similarly,  the  end  diastolic  volume  and  end  systolic  volume  were  also 
significantly different in both the groups.
The  Wall  Motion  Score  Index,  a  novel  index  for  calculating  the  amount  of 
myocardial  jeoparadised  by the ischemic  insult,  also  was significantly  higher  in  the 
study group at 1.98  ±  0.27 versus 1.45  ±  0.18 in the control group, suggesting that 
patients  with  Impaired  Glucose  Tolerance  had  larger  area  of  Left  Ventricular 
myocardium affected by the ischemia and infarction. 
This increase in Wall Motion Score Index positively correlated with the decreased 
ejection fraction and the increase in the incidence of deaths among the study group when 
compared to the control group. 
All patients who died had a Wall Motion Score Index of atleast 1.75 or greater 
with about 8 out of 11 patients (72%) had a Wall Motion Score Index of > 2. Even in the 
control group, where only one death was recorded the patient had a Wall Motion Score 
Index of 1.75.
Thus Wall Motion Score Index had a greater prognostic influence on predicting 
the deaths not only among the patients with Impaired Glucose Tolerance and Acute ST 
elevation Myocardial  Infarction,  but  also  in  patients  with normal  blood glucose  and 
Acute ST elevation Myocardial Infarction. 
Functional capacity was much lower in patients with Impaired Glucose Tolerance 
and Acute ST elevation Myocardial Infarction than in patients with normal glycemia. It 
was 5.02 ±  0.5 Mets in the Impaired Glucose Tolerance group and 6.47 ±  0.96 in the 
control group with a significant ‘p’ value of 0.0001.
Thus,  patient  with  Impaired  Glucose  Tolerance  and  Acute  ST  elevation 
Myocardial Infarction when all other criteria were equally considered had increased in-
hospital  event  rates  like  Arrhythmias,  both  tachyarrhythmias  and  bradyarrhythmias 
(37.3% versus  12%),  increased  incidence  of  Congestive  Heart  Failure  (76%  versus 
16%).
There was also increased incidence of the Recurrent Angina (37.3% versus 12%), 
increased incidence of Left Ventricular Clot (42.7% versus 4%) and increased incidence 
of death (14.7% versus 4%). 
This group also had lesser ejection fraction 40.8  ±  4.6% versus 49.6  ±  3.7%, 
higher Wall Motion Score Index 1.98 ±  0.27 versus 1.45 ±  0.18. There was decrease in 
the functional capacity from 6.47 ±  0.96 in the normoglycemic groups as against 5.02 ±  
0.5 in the Impaired Glucose Tolerance group.
CONCLUSION
 Impaired  Glucose  Tolerance  in  patients  with  Acute  ST  elevation  Myocardial 
Infarction is associated with 
 increased incidence of arrhythmias 
 increased incidence of Congestive Heart Failure 
 increased incidence of recurrent angina 
 increased incidence of Left Ventricular Clot
 increased incidence of in-hospital death
 Impaired Glucose Tolerance is also associated with decrease in the left ventricular 
function as suggested by decrease in the ejection fraction in this group of patients 
and increase in the Wall Motion Score Index. 
 Impaired Glucose Tolerance is associated with decrease in the functional capacity 
during the Pre discharge Treadmill Test.
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IMPAIRED GLUCOSE TOLERANCE IN ACUTE ST ELEVATION 
MYOCARDIAL INFARCTION - A PERSPECTIVE
PROFORMA
NAME : AGE : SEX : ADDRESS:
DOA : CDNO. IPNO. BMI WAIST :
CHEST PAIN :
BREATHLESSNESS : DURATION : NYHA CLASS :
PALPITATION : SYNCOPE : OTHERS :
TYPE OF AMI : STEMI NSTEMI
LOCATION OF INFARCT :
KILLIP’S CLASS :
PREVIOUS DISORDERS : MI ANGINA CHF HTN DM
DYSLIPIDEMIA
SMOKER ALCOHOLIC 
DIET : VEG / NON VEG
ECG
ADMISSION 
90 MINUTES AFTER SK
THROMBOLYSIS SUCCESSFUL / UNSUCCESSFUL
COURSE IN HOSPITAL ;
   DRUGS :   SK      ASA      NITR.    ACEI       BB       STATINS      DIG       HEP    CLOP   AB 
COMPLICATIONS :
ARRHYTHMIAS
CONGESTIVE HEART FAILURE
RECC. ANGINA 
PERICARDITIS
DEATH
OTHERS 
INVESTIGATIONS : URINE : SUGAR KETONE
RBS : BLD UREA SR.CREATININE
75GMS OGTT: FBS : 1HR :  2 HRS ;
TOTAL CHOL : HDL-C LDL-C VLDL-C TGL
ECHO : LVID(d) LVID(s) LVEF MR TR
RWMA :
WALL MOTION SCORE INDEX
STRESS TEST :
THR ACHIEVED HEART RATE BP RESPONSE 
DOUBLE PRODUCT SYMPTOMS 
METS ACHIEVED DURATION OF EXERCISE
ANNEXURE 1
Conversion Table of GHb A1 and GHb A1c
A1 A1c A1 A1c A1 A1c
5.1 3.78 7.7 5.70 10.3 7.63
5.2 3.85 7.8 5.78 10.4 7.70
5.3 3.92 7.9 5.85 10.5 7.78
5.4 4.00 8.0 5.92 10.6 7.85
5.5 4.07 8.1 6.00 10.7 7.92
5.6 4.15 8.2 6.07 10.8 8.00
5.7 4.22 8.3 6.15 10.9 8.07
5.8 4.29 8.4 6.22 11.0 8.15
5.9 4.40 8.5 6.29 11.1 8.22
6.0 4.44 8.6 s6.37 11.2 8.30
6.1 4.48 8.7 6.44 11.3 8.37
6.2 4.59 8.8 6.52 11.4 8.44
6.3 4.70 8.9 6.59 11.5 8.52
6.4 4.74 9.0 6.67 11.6 8.59
6.5 4.81 9.1 6.74
6.6 4.89 9.2 6.81
6.7 4.96 9.3 6.89
6.8 5.04 9.4 6.96
6.9 5.11 9.5 7.04
7.0 5.18 9.6 7.11
7.1 5.26 9.7 7.18
7.2 5.33 9.8 7.26
7.3 5.40 9.9 7.33
7.4 5.48 10.0 7.41
7.5 5.55 10.1 7.48
7.6 5.65 10.2 7.55
ANNEXURE 2
Abbreviations 
Cpdur - Chest pain duration
MI - Myocardial Infarction
Pre. MI - Previous Myocardial Infarction
HTN - Hypertension
Succ. Thrombo  - Successful Thrombolysis
CHF - Congestive Heart Failure
Rec. Angina - Recurrent Angina
SBP - Systolic Blood Pressure
DBP - Diastolic Blood Pressure
PR - Pulse Rate
RBS - Random Blood Sugar
FBS - Fasting Blood Sugar
TC - Total Cholesterol
TGL - Triglycerides
LDL - Low Density Lipoprotein
VLDL - Very Low Density Lipoprotein
BMI - Body Mass Index
EF - Ejection Fraction
EDV - End Diastolic Volume
ESV - End Systolic Volume
WMSI - Wall Motion Score Index
